A Breakthrough Treatment for Eczema
Medical Editor: Leslie J. Schoenfield, MD, PhD
The word "breakthrough" is overused. If every hot item reporters gush about on the evening health news were the real thing, we would have "broken through" a long time ago. Instead, the word is often applied to soon-forgotten advances that aren't and cures that don't.
Every once in a while, however, something new comes along that represents a genuine breakthrough. In 2001, the FDA approved tacrolimus (brand-name: Protopic) for treating eczema, also known as atopic dermatitis. Protopic is the first effective nonsteroid treatment for this common, chronic, itchy condition. A related drug, pimecrolimus (brand-name: Elidel), is now on the market.
These new drugs are referred to as "immune modulators." They were first used internally to help patients with kidney and liver transplants avoid rejecting the organs they received. They work by suppressing the immune system. When these drugs are used externally to treat the skin, however, they do not weaken or change the body's immune system. Also, unlike topical steroids (cortisone creams), these new medications don't cause thinning of the skin and breaking of superficial blood vessels (atrophy).
Medically Reviewed by a Doctor on 12/1/2014
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions